UA83813C2 - Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола - Google Patents

Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола

Info

Publication number
UA83813C2
UA83813C2 UAA200507088A UA2005007088A UA83813C2 UA 83813 C2 UA83813 C2 UA 83813C2 UA A200507088 A UAA200507088 A UA A200507088A UA 2005007088 A UA2005007088 A UA 2005007088A UA 83813 C2 UA83813 C2 UA 83813C2
Authority
UA
Ukraine
Prior art keywords
inhalation
salmeterol xinafoate
tiotropium salt
powdered medicament
treatment
Prior art date
Application number
UAA200507088A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хаген Граэбнер
Мареке Хартиг-Хаймель
Петер Зигер
Райнер Зойка
Михаель Трунк
Михаель Вальц
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA83813(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг
Publication of UA83813C2 publication Critical patent/UA83813C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описаны порошковые составы для ингаляции, которые содержат соль тиотропия и ксинафоат салметерола с температурой плавления, приблизительно, 124 °С, а также их применение для получения лекарственного средства, предназначенного для лечения заболеваний дыхательных путей, прежде всего для лечения хронического обструктивного заболевания легких и астмы.
UAA200507088A 2002-12-20 2003-12-04 Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола UA83813C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20
PCT/EP2003/013691 WO2004058233A1 (de) 2002-12-20 2003-12-04 Pulverförmige arzneimittel zur inhalation enthaltend ein tiotropiumsalz und salmeterolxinafoat

Publications (1)

Publication Number Publication Date
UA83813C2 true UA83813C2 (ru) 2008-08-26

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200507088A UA83813C2 (ru) 2002-12-20 2003-12-04 Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола

Country Status (21)

Country Link
EP (1) EP1581198A1 (ru)
JP (1) JP2006516135A (ru)
KR (1) KR20050086930A (ru)
CN (1) CN1728988B (ru)
AU (1) AU2003288226B2 (ru)
BR (1) BR0317443A (ru)
CA (1) CA2510779A1 (ru)
DE (1) DE10351663A1 (ru)
EA (1) EA010588B1 (ru)
EC (1) ECSP055855A (ru)
FR (1) FR2848849B1 (ru)
HR (1) HRP20050570A2 (ru)
IT (1) ITMI20032473A1 (ru)
MX (1) MXPA05006519A (ru)
NO (1) NO20053548L (ru)
NZ (1) NZ541303A (ru)
PL (1) PL376231A1 (ru)
RS (1) RS20050484A (ru)
UA (1) UA83813C2 (ru)
WO (1) WO2004058233A1 (ru)
ZA (1) ZA200503692B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
CA2617897A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
US8163913B2 (en) * 2005-12-19 2012-04-24 Sicor Inc. Forms of tiotropium bromide and processes for preparation thereof
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
DE102007036411A1 (de) 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
EA202191327A1 (ru) * 2018-11-13 2021-08-09 Кокристал Фарма, Инк. Лекарственные формы терапевтических препаратов от гриппа

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
DE10104367A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
JP2004537377A (ja) * 2001-08-09 2004-12-16 グラクソ グループ リミテッド 製薬組成物を有する吸入装置
MXPA04002401A (es) * 2001-09-14 2004-05-31 Boehringer Ingelheim Pharma Nuevos medicamentos para inhalacion.

Also Published As

Publication number Publication date
FR2848849B1 (fr) 2007-01-05
ECSP055855A (es) 2005-11-22
ZA200503692B (en) 2006-10-25
BR0317443A (pt) 2005-11-16
EA010588B1 (ru) 2008-10-30
FR2848849A1 (fr) 2004-06-25
NO20053548L (no) 2005-09-02
JP2006516135A (ja) 2006-06-22
CN1728988A (zh) 2006-02-01
KR20050086930A (ko) 2005-08-30
NZ541303A (en) 2008-11-28
EP1581198A1 (de) 2005-10-05
DE10351663A1 (de) 2004-07-01
WO2004058233A1 (de) 2004-07-15
MXPA05006519A (es) 2005-08-26
CA2510779A1 (en) 2004-07-15
HRP20050570A2 (en) 2006-07-31
AU2003288226B2 (en) 2010-01-07
PL376231A1 (en) 2005-12-27
RS20050484A (en) 2007-11-15
CN1728988B (zh) 2010-04-28
AU2003288226A1 (en) 2004-07-22
EA200500902A1 (ru) 2006-02-24
ITMI20032473A1 (it) 2004-06-21

Similar Documents

Publication Publication Date Title
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
MY123544A (en) New inhalable powder containing tiotropium
MY155912A (en) New inhalable powder containing tiotropium
MEP30108A (en) Formoterol superfine formulation
TW200708513A (en) Novel crystalline forms of tiotropium bromide
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
CY1114157T1 (el) Αλατα του τιοτροπιου, μεθοδος για την παραγωγη τους και φαρμακευτικα σκευασματα που τα περιεχουν
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
SG149876A1 (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
IL189195A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
MXPA04002401A (es) Nuevos medicamentos para inhalacion.
MXPA04007294A (es) Composicion para inhalacion.
IL189182A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
DK1494648T3 (da) Pulverpræparat til inhalation
WO2005007134A8 (de) Pulverformulierungen für die inhalation enthaltend ein neues anticholinergikum